Key clinical point: Dupilumab with or without topical corticosteroids (TCS) was beneficial in adults with moderate-to-severe atopic dermatitis (AD) regardless of any prior use of systemic nonsteroidal immunosuppressants (NSISS).

Major finding: Compared with placebo with/without TCS, dupilumab with/without TCS showed significant improvement in Eczema Area and Severity Index, SCORing AD, Peak Pruritus Numerical Rating Scale, and quality of life in patients with/without prior use of NSISS (P less than .001) by week 16 which continued through week 52 of treatment.

Study details: Findings are from a post hoc analysis of 4 phase 3 clinical trials including 1553 patients with moderate-to-severe AD randomly assigned to placebo or dupilumab as monotherapy for 16 weeks or with concomitant TCS for 16/52 weeks.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared receiving grants, honoraria and serving as consultant or speaker or on advisory board for various sources. Some of the authors declared being employees and/or holding stocks/stock options at Sanofi, Regeneron Pharmaceuticals, Inc or Sanofi Genzyme.

Source: Griffiths C et al. Dermatol Ther (Heidelb). 2021 Jun 18. doi: 10.1007/s13555-021-00558-0.

Key clinical point: Dupilumab with or without topical corticosteroids (TCS) was beneficial in adults with moderate-to-severe atopic dermatitis (AD) regardless of any prior use of systemic nonsteroidal immunosuppressants (NSISS).

Major finding: Compared with placebo with/without TCS, dupilumab with/without TCS showed significant improvement in Eczema Area and Severity Index, SCORing AD, Peak Pruritus Numerical Rating Scale, and quality of life in patients with/without prior use of NSISS (P less than .001) by week 16 which continued through week 52 of treatment.

Study details: Findings are from a post hoc analysis of 4 phase 3 clinical trials including 1553 patients with moderate-to-severe AD randomly assigned to placebo or dupilumab as monotherapy for 16 weeks or with concomitant TCS for 16/52 weeks.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared receiving grants, honoraria and serving as consultant or speaker or on advisory board for various sources. Some of the authors declared being employees and/or holding stocks/stock options at Sanofi, Regeneron Pharmaceuticals, Inc or Sanofi Genzyme.

Source: Griffiths C et al. Dermatol Ther (Heidelb). 2021 Jun 18. doi: 10.1007/s13555-021-00558-0.

Key clinical point: Dupilumab with or without topical corticosteroids (TCS) was beneficial in adults with moderate-to-severe atopic dermatitis (AD) regardless of any prior use of systemic nonsteroidal immunosuppressants (NSISS).

Major finding: Compared with placebo with/without TCS, dupilumab with/without TCS showed significant improvement in Eczema Area and Severity Index, SCORing AD, Peak Pruritus Numerical Rating Scale, and quality of life in patients with/without prior use of NSISS (P less than .001) by week 16 which continued through week 52 of treatment.

Study details: Findings are from a post hoc analysis of 4 phase 3 clinical trials including 1553 patients with moderate-to-severe AD randomly assigned to placebo or dupilumab as monotherapy for 16 weeks or with concomitant TCS for 16/52 weeks.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Some of the authors declared receiving grants, honoraria and serving as consultant or speaker or on advisory board for various sources. Some of the authors declared being employees and/or holding stocks/stock options at Sanofi, Regeneron Pharmaceuticals, Inc or Sanofi Genzyme.

Source: Griffiths C et al. Dermatol Ther (Heidelb). 2021 Jun 18. doi: 10.1007/s13555-021-00558-0.

Key clinical point: In real world clinical practice, combination of tacrolimus ointment and dupilumab was an effective and safe treatment option for facial atopic dermatitis (AD).

Major finding: On 16 weeks of treatment, a significant decrease was observed in average scores including Investigator’s Global Assessment, overall Eczema Area and Severity Index (EASI), and head/neck EASI (P less than .0001). Moreover, the rate of improvement in head/neck EASI scores significantly correlated with the rate of improvement in the overall EASI scores (Pearson’s r, 0.61; P less than .01). None of the patients developed herpes simplex, whereas 2 patients developed conjunctivitis.

Study details: Findings are from a retrospective chart review of 109 patients with moderate-to-severe AD who initiated dupilumab, of which 60 patients also used tacrolimus ointment. Of these, 20 patients used tacrolimus ointment without any topical steroids.

Disclosures: This work was supported by grants from Japan Society for the Promotion of Science. The authors did not declare any conflicts of interest.

Source: Matsutani M et al. J Dermatol. 2021 Jun 22. doi: 10.1111/1346-8138.16039.

Key clinical point: In real world clinical practice, combination of tacrolimus ointment and dupilumab was an effective and safe treatment option for facial atopic dermatitis (AD).

Major finding: On 16 weeks of treatment, a significant decrease was observed in average scores including Investigator’s Global Assessment, overall Eczema Area and Severity Index (EASI), and head/neck EASI (P less than .0001). Moreover, the rate of improvement in head/neck EASI scores significantly correlated with the rate of improvement in the overall EASI scores (Pearson’s r, 0.61; P less than .01). None of the patients developed herpes simplex, whereas 2 patients developed conjunctivitis.

Study details: Findings are from a retrospective chart review of 109 patients with moderate-to-severe AD who initiated dupilumab, of which 60 patients also used tacrolimus ointment. Of these, 20 patients used tacrolimus ointment without any topical steroids.

Disclosures: This work was supported by grants from Japan Society for the Promotion of Science. The authors did not declare any conflicts of interest.

Source: Matsutani M et al. J Dermatol. 2021 Jun 22. doi: 10.1111/1346-8138.16039.

Key clinical point: In real world clinical practice, combination of tacrolimus ointment and dupilumab was an effective and safe treatment option for facial atopic dermatitis (AD).

Major finding: On 16 weeks of treatment, a significant decrease was observed in average scores including Investigator’s Global Assessment, overall Eczema Area and Severity Index (EASI), and head/neck EASI (P less than .0001). Moreover, the rate of improvement in head/neck EASI scores significantly correlated with the rate of improvement in the overall EASI scores (Pearson’s r, 0.61; P less than .01). None of the patients developed herpes simplex, whereas 2 patients developed conjunctivitis.

Study details: Findings are from a retrospective chart review of 109 patients with moderate-to-severe AD who initiated dupilumab, of which 60 patients also used tacrolimus ointment. Of these, 20 patients used tacrolimus ointment without any topical steroids.

Disclosures: This work was supported by grants from Japan Society for the Promotion of Science. The authors did not declare any conflicts of interest.

Source: Matsutani M et al. J Dermatol. 2021 Jun 22. doi: 10.1111/1346-8138.16039.

Key clinical point: Baricitinib therapy resulted in clinically meaningful improvement in itch severity leading to significantly better quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: By week 16, higher proportion of patients receiving baricitinib 2 mg (25.2%; P less than .0001) and 1 mg (15.9%; P = .0114) vs placebo (5.7%) experienced improvements in itch severity. Higher proportion of patients with vs without itch improvement showed no impact of AD on QoL (P less than .0001).

Study details: Findings are from a post hoc analysis of phase 3 trial, BREEZE-AD5 involving 440 adults with moderate-to-severe AD who received baricitinib 1 mg, 2 mg, or placebo once daily.

Disclosures: This work was funded by Eli Lilly and Company. Some of the authors declared receiving grants, funding, consulting fees, and/or honoraria from and/or serving as board member, speaker, advisor, and/or investigator for various sources including Eli Lilly. Five of the authors declared being employees and shareholders of Eli Lilly.

Source: Lio PA et al. J Dermatolog Treat. 2021 Jun 28. doi: 10.1080/09546634.2021.1914308.

Key clinical point: Baricitinib therapy resulted in clinically meaningful improvement in itch severity leading to significantly better quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: By week 16, higher proportion of patients receiving baricitinib 2 mg (25.2%; P less than .0001) and 1 mg (15.9%; P = .0114) vs placebo (5.7%) experienced improvements in itch severity. Higher proportion of patients with vs without itch improvement showed no impact of AD on QoL (P less than .0001).

Study details: Findings are from a post hoc analysis of phase 3 trial, BREEZE-AD5 involving 440 adults with moderate-to-severe AD who received baricitinib 1 mg, 2 mg, or placebo once daily.

Disclosures: This work was funded by Eli Lilly and Company. Some of the authors declared receiving grants, funding, consulting fees, and/or honoraria from and/or serving as board member, speaker, advisor, and/or investigator for various sources including Eli Lilly. Five of the authors declared being employees and shareholders of Eli Lilly.

Source: Lio PA et al. J Dermatolog Treat. 2021 Jun 28. doi: 10.1080/09546634.2021.1914308.

Key clinical point: Baricitinib therapy resulted in clinically meaningful improvement in itch severity leading to significantly better quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: By week 16, higher proportion of patients receiving baricitinib 2 mg (25.2%; P less than .0001) and 1 mg (15.9%; P = .0114) vs placebo (5.7%) experienced improvements in itch severity. Higher proportion of patients with vs without itch improvement showed no impact of AD on QoL (P less than .0001).

Study details: Findings are from a post hoc analysis of phase 3 trial, BREEZE-AD5 involving 440 adults with moderate-to-severe AD who received baricitinib 1 mg, 2 mg, or placebo once daily.

Disclosures: This work was funded by Eli Lilly and Company. Some of the authors declared receiving grants, funding, consulting fees, and/or honoraria from and/or serving as board member, speaker, advisor, and/or investigator for various sources including Eli Lilly. Five of the authors declared being employees and shareholders of Eli Lilly.

Source: Lio PA et al. J Dermatolog Treat. 2021 Jun 28. doi: 10.1080/09546634.2021.1914308.

Key clinical point: Abrocitinib monotherapy was associated with a rapid and profound relief in atopic dermatitis (AD) itch.

Major finding: A higher proportion of patients receiving abrocitinib 200 mg and 100 mg vs placebo experienced clinically meaningful itch improvement at week 2 (44.2% and 24.9% vs 5.8%), which continued through week 12 (57.3% and 42.9% vs 16.5%; both P less than .05). Mean percentage reductions in itch scores 24 hours after the first dose were greater for abrocitinib 200 mg and 100 mg vs placebo which was maintained through week 12 (−56.1 and −42.3 vs −19.5).

Study details: Findings are from a pooled analysis of 1 phase 2b (NCT02780167) and 2 phase 3 (JADE MONO-1 and JADE MONO-2) trials including 942 patients with moderate-to-severe AD who received abrocitinib 200 mg, abrocitinib 100 mg, or placebo.

Disclosures: This study was sponsored by Pfizer, Inc. Some of the authors declared receiving grants and personal fees and/or serving as consultant, speaker, advisor, and/or principal investigator for various sources including Pfizer. Six of the authors declared being employees and shareholders of Pfizer, Inc.

Source: Kim BS et al. Dermatitis. 2021 Jul 7. doi: 10.1097/DER.0000000000000770.

Key clinical point: Abrocitinib monotherapy was associated with a rapid and profound relief in atopic dermatitis (AD) itch.

Major finding: A higher proportion of patients receiving abrocitinib 200 mg and 100 mg vs placebo experienced clinically meaningful itch improvement at week 2 (44.2% and 24.9% vs 5.8%), which continued through week 12 (57.3% and 42.9% vs 16.5%; both P less than .05). Mean percentage reductions in itch scores 24 hours after the first dose were greater for abrocitinib 200 mg and 100 mg vs placebo which was maintained through week 12 (−56.1 and −42.3 vs −19.5).

Study details: Findings are from a pooled analysis of 1 phase 2b (NCT02780167) and 2 phase 3 (JADE MONO-1 and JADE MONO-2) trials including 942 patients with moderate-to-severe AD who received abrocitinib 200 mg, abrocitinib 100 mg, or placebo.

Disclosures: This study was sponsored by Pfizer, Inc. Some of the authors declared receiving grants and personal fees and/or serving as consultant, speaker, advisor, and/or principal investigator for various sources including Pfizer. Six of the authors declared being employees and shareholders of Pfizer, Inc.

Source: Kim BS et al. Dermatitis. 2021 Jul 7. doi: 10.1097/DER.0000000000000770.

Key clinical point: Abrocitinib monotherapy was associated with a rapid and profound relief in atopic dermatitis (AD) itch.

Major finding: A higher proportion of patients receiving abrocitinib 200 mg and 100 mg vs placebo experienced clinically meaningful itch improvement at week 2 (44.2% and 24.9% vs 5.8%), which continued through week 12 (57.3% and 42.9% vs 16.5%; both P less than .05). Mean percentage reductions in itch scores 24 hours after the first dose were greater for abrocitinib 200 mg and 100 mg vs placebo which was maintained through week 12 (−56.1 and −42.3 vs −19.5).

Study details: Findings are from a pooled analysis of 1 phase 2b (NCT02780167) and 2 phase 3 (JADE MONO-1 and JADE MONO-2) trials including 942 patients with moderate-to-severe AD who received abrocitinib 200 mg, abrocitinib 100 mg, or placebo.

Disclosures: This study was sponsored by Pfizer, Inc. Some of the authors declared receiving grants and personal fees and/or serving as consultant, speaker, advisor, and/or principal investigator for various sources including Pfizer. Six of the authors declared being employees and shareholders of Pfizer, Inc.

Source: Kim BS et al. Dermatitis. 2021 Jul 7. doi: 10.1097/DER.0000000000000770.

Key clinical point: Majority of patients with atopic dermatitis (AD) who tested positive for COVID-19 experienced subclinical infection; however, extended treatment with systemic corticosteroids during the pandemic increased chances of COVID-19-associated hospitalization.

Major finding: Most (93.1%) of the COVID-19 infections in patients with AD were subclinical. COVID-19-related complications resulted in 6% hospitalizations, 0.3% mechanical ventilations, and 1.1% deaths. Intake of systemic corticosteroids for 2 or more months during the pandemic was associated with hospitalizations related to COVID-19 (adjusted odds ratio, 1.96; P = .005). However, mortality associated with COVID-19 was not predicted by AD-related variables.

Study details: Findings are from a nested case-control study including 3618 patients with AD who tested positive for COVID-19.

Disclosures: No funding source was identified. Dr. Cohen declared serving as an advisor, investigator, or speaker for various sources. The other authors had no disclosures.

Source: Kridin K et al. Dermatitis. 2021 Jun 15. doi: 10.1097/DER.0000000000000772.

Key clinical point: Majority of patients with atopic dermatitis (AD) who tested positive for COVID-19 experienced subclinical infection; however, extended treatment with systemic corticosteroids during the pandemic increased chances of COVID-19-associated hospitalization.

Major finding: Most (93.1%) of the COVID-19 infections in patients with AD were subclinical. COVID-19-related complications resulted in 6% hospitalizations, 0.3% mechanical ventilations, and 1.1% deaths. Intake of systemic corticosteroids for 2 or more months during the pandemic was associated with hospitalizations related to COVID-19 (adjusted odds ratio, 1.96; P = .005). However, mortality associated with COVID-19 was not predicted by AD-related variables.

Study details: Findings are from a nested case-control study including 3618 patients with AD who tested positive for COVID-19.

Disclosures: No funding source was identified. Dr. Cohen declared serving as an advisor, investigator, or speaker for various sources. The other authors had no disclosures.

Source: Kridin K et al. Dermatitis. 2021 Jun 15. doi: 10.1097/DER.0000000000000772.

Key clinical point: Majority of patients with atopic dermatitis (AD) who tested positive for COVID-19 experienced subclinical infection; however, extended treatment with systemic corticosteroids during the pandemic increased chances of COVID-19-associated hospitalization.

Major finding: Most (93.1%) of the COVID-19 infections in patients with AD were subclinical. COVID-19-related complications resulted in 6% hospitalizations, 0.3% mechanical ventilations, and 1.1% deaths. Intake of systemic corticosteroids for 2 or more months during the pandemic was associated with hospitalizations related to COVID-19 (adjusted odds ratio, 1.96; P = .005). However, mortality associated with COVID-19 was not predicted by AD-related variables.

Study details: Findings are from a nested case-control study including 3618 patients with AD who tested positive for COVID-19.

Disclosures: No funding source was identified. Dr. Cohen declared serving as an advisor, investigator, or speaker for various sources. The other authors had no disclosures.

Source: Kridin K et al. Dermatitis. 2021 Jun 15. doi: 10.1097/DER.0000000000000772.

Key clinical point: Delgocitinib ointment was effective and safe for up to 56 weeks in pediatric patients with atopic dermatitis (AD).

Major finding: By the end of initial 4-week treatment, least-squares mean percentage change from baseline in the modified Eczema Area and Severity Index (mEASI) score was significantly greater for delgocitinib vs vehicle (−39.3% vs +10.9%; P less than .001) groups. Improvement in mEASI score continued through the 52-week extension phase. Treatment-related mild adverse events were reported by only 9.7% of patients.

Study details: Findings are from a phase 3 study including 137 Japanese patients aged 2-15 years with mild/moderate/severe AD randomly allocated to either delgocitinib (0.25%) or vehicle ointment for 4 weeks. Eligible patients entered the 52-week extension study phase to receive 0.25% or 0.5% delgocitinib ointment.

Disclosures: This study was funded by Japan Tobacco Inc. and Torii Pharmaceutical Co, Ltd. Some of the authors declared receiving consulting fees, research grants, speaker honoraria, and/or advisory board honoraria from various sources including Japan Tobacco Inc. Two authors declared being employees of Japan Tobacco Inc.

Source: Nakagawa H et al. J Am Acad Dermatol. 2021 Jun 9. doi: 10.1016/j.jaad.2021.06.014.

Key clinical point: Delgocitinib ointment was effective and safe for up to 56 weeks in pediatric patients with atopic dermatitis (AD).

Major finding: By the end of initial 4-week treatment, least-squares mean percentage change from baseline in the modified Eczema Area and Severity Index (mEASI) score was significantly greater for delgocitinib vs vehicle (−39.3% vs +10.9%; P less than .001) groups. Improvement in mEASI score continued through the 52-week extension phase. Treatment-related mild adverse events were reported by only 9.7% of patients.

Study details: Findings are from a phase 3 study including 137 Japanese patients aged 2-15 years with mild/moderate/severe AD randomly allocated to either delgocitinib (0.25%) or vehicle ointment for 4 weeks. Eligible patients entered the 52-week extension study phase to receive 0.25% or 0.5% delgocitinib ointment.

Disclosures: This study was funded by Japan Tobacco Inc. and Torii Pharmaceutical Co, Ltd. Some of the authors declared receiving consulting fees, research grants, speaker honoraria, and/or advisory board honoraria from various sources including Japan Tobacco Inc. Two authors declared being employees of Japan Tobacco Inc.

Source: Nakagawa H et al. J Am Acad Dermatol. 2021 Jun 9. doi: 10.1016/j.jaad.2021.06.014.

Key clinical point: Delgocitinib ointment was effective and safe for up to 56 weeks in pediatric patients with atopic dermatitis (AD).

Major finding: By the end of initial 4-week treatment, least-squares mean percentage change from baseline in the modified Eczema Area and Severity Index (mEASI) score was significantly greater for delgocitinib vs vehicle (−39.3% vs +10.9%; P less than .001) groups. Improvement in mEASI score continued through the 52-week extension phase. Treatment-related mild adverse events were reported by only 9.7% of patients.

Study details: Findings are from a phase 3 study including 137 Japanese patients aged 2-15 years with mild/moderate/severe AD randomly allocated to either delgocitinib (0.25%) or vehicle ointment for 4 weeks. Eligible patients entered the 52-week extension study phase to receive 0.25% or 0.5% delgocitinib ointment.

Disclosures: This study was funded by Japan Tobacco Inc. and Torii Pharmaceutical Co, Ltd. Some of the authors declared receiving consulting fees, research grants, speaker honoraria, and/or advisory board honoraria from various sources including Japan Tobacco Inc. Two authors declared being employees of Japan Tobacco Inc.

Source: Nakagawa H et al. J Am Acad Dermatol. 2021 Jun 9. doi: 10.1016/j.jaad.2021.06.014.

Key clinical point: A topical cream containing cultured autologous antimicrobial-producing coagulase-negative strain of Staphylococcus (CoNS-AM+) safely decreased Staphylococcus aureus colonization and improved disease severity in patients with atopic dermatitis (AD).

Major finding: At the end of treatment, CoNS-AM+ reduced S. aureus colonization on lesioned skin by 99.2% compared with the vehicle (mean of log10 ratio to baseline, −1.702 vs 0.671; P = .01), which persisted even 4 days after treatment (P = .03). On day 11, Eczema Area and Severity Index scores improved significantly in patients receiving CoNS-AM+ vs vehicle (P = .04). No serious adverse events were recorded in either group.

Study details: This was a double-blind, vehicle-controlled randomized clinical trial of 11 adult patients with moderate-to-severe AD randomly assigned to either CoNS-AM+ (n=5) or the vehicle (n=6).

Disclosures: This work was supported by grants from the National Institute of Health. Dr. Nakatsuji, Dr. Gallo, and Dr. Shafiq reported receiving grants and/or consulting fees from and holding patent/pending patent, and/or holding equity in various sources.

Source: Nakatsuji T et al. JAMA Dermatol. 2021 Jun 16. doi: 10.1001/jamadermatol.2021.1311.

Key clinical point: A topical cream containing cultured autologous antimicrobial-producing coagulase-negative strain of Staphylococcus (CoNS-AM+) safely decreased Staphylococcus aureus colonization and improved disease severity in patients with atopic dermatitis (AD).

Major finding: At the end of treatment, CoNS-AM+ reduced S. aureus colonization on lesioned skin by 99.2% compared with the vehicle (mean of log10 ratio to baseline, −1.702 vs 0.671; P = .01), which persisted even 4 days after treatment (P = .03). On day 11, Eczema Area and Severity Index scores improved significantly in patients receiving CoNS-AM+ vs vehicle (P = .04). No serious adverse events were recorded in either group.

Study details: This was a double-blind, vehicle-controlled randomized clinical trial of 11 adult patients with moderate-to-severe AD randomly assigned to either CoNS-AM+ (n=5) or the vehicle (n=6).

Disclosures: This work was supported by grants from the National Institute of Health. Dr. Nakatsuji, Dr. Gallo, and Dr. Shafiq reported receiving grants and/or consulting fees from and holding patent/pending patent, and/or holding equity in various sources.

Source: Nakatsuji T et al. JAMA Dermatol. 2021 Jun 16. doi: 10.1001/jamadermatol.2021.1311.

Key clinical point: A topical cream containing cultured autologous antimicrobial-producing coagulase-negative strain of Staphylococcus (CoNS-AM+) safely decreased Staphylococcus aureus colonization and improved disease severity in patients with atopic dermatitis (AD).

Major finding: At the end of treatment, CoNS-AM+ reduced S. aureus colonization on lesioned skin by 99.2% compared with the vehicle (mean of log10 ratio to baseline, −1.702 vs 0.671; P = .01), which persisted even 4 days after treatment (P = .03). On day 11, Eczema Area and Severity Index scores improved significantly in patients receiving CoNS-AM+ vs vehicle (P = .04). No serious adverse events were recorded in either group.

Study details: This was a double-blind, vehicle-controlled randomized clinical trial of 11 adult patients with moderate-to-severe AD randomly assigned to either CoNS-AM+ (n=5) or the vehicle (n=6).

Disclosures: This work was supported by grants from the National Institute of Health. Dr. Nakatsuji, Dr. Gallo, and Dr. Shafiq reported receiving grants and/or consulting fees from and holding patent/pending patent, and/or holding equity in various sources.

Source: Nakatsuji T et al. JAMA Dermatol. 2021 Jun 16. doi: 10.1001/jamadermatol.2021.1311.

Key clinical point: Fecal-based screening for colorectal cancer (CRC) was associated with a significant reduction in CRC mortality.

Major finding: Overall, 624 participants were diagnosed with CRC, of which 42.5% were detected by fecal occult blood test (FOBT) screening (screen-detected), 16.5% presented after a negative FOBT and before the next invitation (interval cancers), and 41.0% were among individuals who declined screening (nonuptake cancers). Mortality rate was 74% higher in interval CRC vsvs screen-detected CRC (adjusted hazard ratio, 1.74%; P = .02).

Study details: Findings are from a retrospective cohort of invitees aged 50–69 years who participated in a CRC screening program with a target population of 85,000 people from 2000-2015 with mortality follow-up until 2020.

Disclosures: This study received no specific funding. The authors declared no competing interest.

Source: Ibáñez-Sanz G et al. PLoS One. 2021 Jun 30. doi: 10.1371/journal.pone.0253369.

Key clinical point: Fecal-based screening for colorectal cancer (CRC) was associated with a significant reduction in CRC mortality.

Major finding: Overall, 624 participants were diagnosed with CRC, of which 42.5% were detected by fecal occult blood test (FOBT) screening (screen-detected), 16.5% presented after a negative FOBT and before the next invitation (interval cancers), and 41.0% were among individuals who declined screening (nonuptake cancers). Mortality rate was 74% higher in interval CRC vsvs screen-detected CRC (adjusted hazard ratio, 1.74%; P = .02).

Study details: Findings are from a retrospective cohort of invitees aged 50–69 years who participated in a CRC screening program with a target population of 85,000 people from 2000-2015 with mortality follow-up until 2020.

Disclosures: This study received no specific funding. The authors declared no competing interest.

Source: Ibáñez-Sanz G et al. PLoS One. 2021 Jun 30. doi: 10.1371/journal.pone.0253369.

Key clinical point: Fecal-based screening for colorectal cancer (CRC) was associated with a significant reduction in CRC mortality.

Major finding: Overall, 624 participants were diagnosed with CRC, of which 42.5% were detected by fecal occult blood test (FOBT) screening (screen-detected), 16.5% presented after a negative FOBT and before the next invitation (interval cancers), and 41.0% were among individuals who declined screening (nonuptake cancers). Mortality rate was 74% higher in interval CRC vsvs screen-detected CRC (adjusted hazard ratio, 1.74%; P = .02).

Study details: Findings are from a retrospective cohort of invitees aged 50–69 years who participated in a CRC screening program with a target population of 85,000 people from 2000-2015 with mortality follow-up until 2020.

Disclosures: This study received no specific funding. The authors declared no competing interest.

Source: Ibáñez-Sanz G et al. PLoS One. 2021 Jun 30. doi: 10.1371/journal.pone.0253369.

Key clinical point: The risk for incident colorectal cancer (CRC) events increases with the presence of normal-high fasting plasma glucose (FPG), impaired fasting glucose (IFG), and diabetes mellitus (DM).

Major finding: Compared with normal FPG, the presence of normal-high FPG (hazard ratio [HR], 1.10; 95% confidence interval [CI], 1.03-1.18), IFG (HR, 1.24; 95% CI, 1.13-1.37), and DM (HR, 1.36; 95% CI, 1.19-1.55) was associated with a higher incidence rate of CRC.

Study details: Findings are from a retrospective observational study of 1,441,311 individuals who underwent annual health checkups. Included patients did not have colorectal polyps, Crohn's disease, and/or ulcerative colitis and were not taking antidiabetic medications.

Disclosures: The study was supported by grants from the Ministry of Health, Labour, and Welfare and the Ministry of Education, Culture, Sports, Science, and Technology, Japan. H Kaneko and K Fujiu declared receiving research funding and scholarship funds from various sources.

Source: Itoh H et al. J Clin Endocrinol Metab. 2021 Jun 25. doi: 10.1210/clinem/dgab466.

Key clinical point: The risk for incident colorectal cancer (CRC) events increases with the presence of normal-high fasting plasma glucose (FPG), impaired fasting glucose (IFG), and diabetes mellitus (DM).

Major finding: Compared with normal FPG, the presence of normal-high FPG (hazard ratio [HR], 1.10; 95% confidence interval [CI], 1.03-1.18), IFG (HR, 1.24; 95% CI, 1.13-1.37), and DM (HR, 1.36; 95% CI, 1.19-1.55) was associated with a higher incidence rate of CRC.

Study details: Findings are from a retrospective observational study of 1,441,311 individuals who underwent annual health checkups. Included patients did not have colorectal polyps, Crohn's disease, and/or ulcerative colitis and were not taking antidiabetic medications.

Disclosures: The study was supported by grants from the Ministry of Health, Labour, and Welfare and the Ministry of Education, Culture, Sports, Science, and Technology, Japan. H Kaneko and K Fujiu declared receiving research funding and scholarship funds from various sources.

Source: Itoh H et al. J Clin Endocrinol Metab. 2021 Jun 25. doi: 10.1210/clinem/dgab466.

Key clinical point: The risk for incident colorectal cancer (CRC) events increases with the presence of normal-high fasting plasma glucose (FPG), impaired fasting glucose (IFG), and diabetes mellitus (DM).

Major finding: Compared with normal FPG, the presence of normal-high FPG (hazard ratio [HR], 1.10; 95% confidence interval [CI], 1.03-1.18), IFG (HR, 1.24; 95% CI, 1.13-1.37), and DM (HR, 1.36; 95% CI, 1.19-1.55) was associated with a higher incidence rate of CRC.

Study details: Findings are from a retrospective observational study of 1,441,311 individuals who underwent annual health checkups. Included patients did not have colorectal polyps, Crohn's disease, and/or ulcerative colitis and were not taking antidiabetic medications.

Disclosures: The study was supported by grants from the Ministry of Health, Labour, and Welfare and the Ministry of Education, Culture, Sports, Science, and Technology, Japan. H Kaneko and K Fujiu declared receiving research funding and scholarship funds from various sources.

Source: Itoh H et al. J Clin Endocrinol Metab. 2021 Jun 25. doi: 10.1210/clinem/dgab466.

Key clinical point: Patients diagnosed with colorectal cancer (CRC) at an early age showed modest survival advantage over those diagnosed at a later age, particularly in patients with early-stage cancer. Findings emphasize on the importance of early CRC detection in the younger population.

Major finding: After adjustments, most notably for stage, patients with CRC diagnosed at an age younger than 50 years vsvs 51-55 years had a lower risk for death (hazard ratio [HR], 0.95; P less than .001). The advantage of reduced mortality was greatest in patients diagnosed between 35 and 39 years of age (adjusted HR, 0.88; P less than .001) and limited to individuals diagnosed at stages I and II (both P less than .001).

Study details: Findings are from a cohort study of 769,871 patients from the National Cancer Database, who were diagnosed with primary CRC.

Disclosures: The study was funded by the National Institutes of Health and American Association for Cancer Research grant to Stand Up To Cancer, a division of the Entertainment Industry Foundation. Some of the authors reported receiving grants and personal fees, speaking fees, and serving as a consultant for various sources.

Source: Cheng E et al. JAMA Netw Open. 2021 Jun 16. doi:10.1001/jamanetworkopen.2021.12539.

Key clinical point: Patients diagnosed with colorectal cancer (CRC) at an early age showed modest survival advantage over those diagnosed at a later age, particularly in patients with early-stage cancer. Findings emphasize on the importance of early CRC detection in the younger population.

Major finding: After adjustments, most notably for stage, patients with CRC diagnosed at an age younger than 50 years vsvs 51-55 years had a lower risk for death (hazard ratio [HR], 0.95; P less than .001). The advantage of reduced mortality was greatest in patients diagnosed between 35 and 39 years of age (adjusted HR, 0.88; P less than .001) and limited to individuals diagnosed at stages I and II (both P less than .001).

Study details: Findings are from a cohort study of 769,871 patients from the National Cancer Database, who were diagnosed with primary CRC.

Disclosures: The study was funded by the National Institutes of Health and American Association for Cancer Research grant to Stand Up To Cancer, a division of the Entertainment Industry Foundation. Some of the authors reported receiving grants and personal fees, speaking fees, and serving as a consultant for various sources.

Source: Cheng E et al. JAMA Netw Open. 2021 Jun 16. doi:10.1001/jamanetworkopen.2021.12539.

Key clinical point: Patients diagnosed with colorectal cancer (CRC) at an early age showed modest survival advantage over those diagnosed at a later age, particularly in patients with early-stage cancer. Findings emphasize on the importance of early CRC detection in the younger population.

Major finding: After adjustments, most notably for stage, patients with CRC diagnosed at an age younger than 50 years vsvs 51-55 years had a lower risk for death (hazard ratio [HR], 0.95; P less than .001). The advantage of reduced mortality was greatest in patients diagnosed between 35 and 39 years of age (adjusted HR, 0.88; P less than .001) and limited to individuals diagnosed at stages I and II (both P less than .001).

Study details: Findings are from a cohort study of 769,871 patients from the National Cancer Database, who were diagnosed with primary CRC.

Disclosures: The study was funded by the National Institutes of Health and American Association for Cancer Research grant to Stand Up To Cancer, a division of the Entertainment Industry Foundation. Some of the authors reported receiving grants and personal fees, speaking fees, and serving as a consultant for various sources.

Source: Cheng E et al. JAMA Netw Open. 2021 Jun 16. doi:10.1001/jamanetworkopen.2021.12539.